Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) : Investors Should Not Dump ARCT Stock In 2024

In the latest trading session,, 0.51 million Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) shares changed hands as the company’s beta touched 2.69. With the company’s most recent per share price at $37.66 changing hands around $7.25 or 23.84% at last look, the market valuation stands at $1.01B. ARCT’s current price is a discount, trading about -16.33% off its 52-week high of $43.81. The share price had its 52-week low at $17.52, which suggests the last value was 53.48% up since then. When we look at Arcturus Therapeutics Holdings Inc’s average trading volume, we note the 3-month average coming to 508.70K.

Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) trade information

Instantly ARCT is in green as seen in intraday trades today. With action 23.48%, the performance over the past five days has been green. The jump to weekly highs of 37.74 added 23.84% to the stock’s daily price. The company’s shares are showing year-to-date upside of 19.44%, with the 5-day performance at 23.48% in the green. However, in the 30-day time frame, Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) is 41.85% up.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Arcturus Therapeutics Holdings Inc (ARCT) estimates and forecasts

Data shows that the Arcturus Therapeutics Holdings Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 57.51% over the past 6 months, a -120.60% in annual growth rate that is considerably lower than the industry average of 15.30%. Year-over-year growth is forecast to reach 7.00% up from the last financial year.

Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of 21.7M. 7 analysts are of the opinion that Arcturus Therapeutics Holdings Inc’s revenue for the current quarter will be 46.7M. The company’s revenue for the corresponding quarters a year ago was 10.52M and 45.14M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 106.30%. The estimates for the next quarter sales put growth at 3.50%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 12.40%. The 2024 estimates are for Arcturus Therapeutics Holdings Inc earnings to decrease by -233.66%.